Afficher la notice abrégée

Resistance to integrase inhibitors: a national study in HIV -1-infected treatment-naive and -experienced patients

dc.rights.licenseopenen_US
dc.contributor.authorMARCELIN, Anne-Geneviève
dc.contributor.authorGRUDE, Maxime
dc.contributor.authorCHARPENTIER, Charlotte
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBELLECAVE, Pantxika
dc.contributor.authorLE GUEN, Laura
dc.contributor.authorPALLIER, Coralie
dc.contributor.authorRAYMOND, Stéphanie
dc.contributor.authorMIRAND, Audrey
dc.contributor.authorBOCKET, Laurence
dc.contributor.authorFOFANA, Djeneba Bocar
dc.contributor.authorDELAUGERRE, Constance
dc.contributor.authorNGUYEN, Thuy
dc.contributor.authorMONTES, Brigitte
dc.contributor.authorJEULIN, Helène
dc.contributor.authorMOUREZ, Thomas
dc.contributor.authorFAFI-KREMER, Samira
dc.contributor.authorAMIEL, Corinne
dc.contributor.authorROUSSEL, Catherine
dc.contributor.authorDINA, Julia
dc.contributor.authorTRABAUD, Mary-Anne
dc.contributor.authorLE GUILLOU-GUILLEMETTE, Hélène
dc.contributor.authorVALLET, Sophie
dc.contributor.authorSIGNORI-SCHMUCK, Anne
dc.contributor.authorMAILLARD, Anne
dc.contributor.authorFERRÉ, Virginie
dc.contributor.authorDESCAMPS, Diane
dc.contributor.authorCALVEZ, Vincent
dc.contributor.authorFLANDRE, Philippe
dc.date.accessioned2023-06-14T10:06:43Z
dc.date.available2023-06-14T10:06:43Z
dc.date.issued2019-02-20
dc.identifier.issn0305-7453en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182678
dc.description.abstractEnObjectives: To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing an INSTI-based regimen in clinical practice.Methods: Data were collected from patients failing an INSTI-containing regimen in a multicentre French study between 2014 and 2017. Failure was defined as two consecutive plasma viral loads (VL) >50 copies/mL. Reverse transcriptase, protease and integrase coding regions were sequenced at baseline and failure. INSTI resistance-associated mutations (RAMs) included in the Agence Nationale de Recherches sur le SIDA genotypic algorithm were investigated.Results: Among the 674 patients, 359 were failing on raltegravir, 154 on elvitegravir and 161 on dolutegravir therapy. Overall, 90% were experienced patients and 389 (58%) patients showed no INSTI RAMs at failure. The strongest factors associated with emergence of at least one INSTI mutation were high VL at failure (OR = 1.2 per 1 log10 copies/mL increase) and low genotypic sensitivity score (GSS) (OR = 0.08 for GSS ≥3 versus GSS = 0-0.5). Patients failing dolutegravir also had significantly fewer INSTI RAMs at failure than patients failing raltegravir (OR = 0.57, P = 0.02) or elvitegravir (OR = 0.45, P = 0.005). Among the 68 patients failing a first-line regimen, 11/41 (27%) patients on raltegravir, 7/18 (39%) on elvitegravir and 0/9 on dolutegravir had viruses with emergent INSTI RAMs at failure.Conclusions: These results confirmed the robustness of dolutegravir regarding resistance selection in integrase in the case of virological failure in routine clinical care.
dc.language.isoENen_US
dc.subject.meshAdult
dc.subject.meshDrug Resistance, Multiple, Viral / genetics
dc.subject.meshGenotype
dc.subject.meshHIV Infections / drug therapy
dc.subject.meshHIV Integrase Inhibitors / therapeutic use
dc.subject.meshHIV Seropositivity / drug therapy
dc.subject.meshHIV-1 / drug effects
dc.subject.meshHIV-1 / genetics
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMutation
dc.subject.meshRisk Factors
dc.subject.meshSequence Analysis, DNA
dc.subject.meshTreatment Failure
dc.subject.meshViral Load / drug effects
dc.subject.meshFemale
dc.title.enResistance to integrase inhibitors: a national study in HIV -1-infected treatment-naive and -experienced patients
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jac/dkz021en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologieen_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologie/Bactériologieen_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
bordeaux.journalJournal of Antimicrobial Chemotherapyen_US
bordeaux.page1368-1375en_US
bordeaux.volume74en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue5en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-02154049
hal.version1
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Antimicrobial%20Chemotherapy&rft.date=2019-02-20&rft.volume=74&rft.issue=5&rft.spage=1368-1375&rft.epage=1368-1375&rft.eissn=0305-7453&rft.issn=0305-7453&rft.au=MARCELIN,%20Anne-Genevi%C3%A8ve&GRUDE,%20Maxime&CHARPENTIER,%20Charlotte&BELLECAVE,%20Pantxika&LE%20GUEN,%20Laura&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MFP_Jac_2019_Marcelin.pdf
Taille:
229.4Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée